Professor of Oncology
Breast Cancer Program
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University
Dr. Wolff serves as the Executive Officer of the Translational Breast Cancer Research Consortium (TBCRC) (www.tbcrc.org), a clinical research consortium, initiated in 2005 with support from BCRF, that unites the efforts of many leading breast cancer programs from top academic medical centers throughout the United States. The Consortium, led by laboratory scientists and clinical researchers, pursues focused clinical trials that integrate clinical and laboratory studies in an effort to accelerate progress in breast cancer clinical research. Since its inception, 30 TBCRC clinical trials have been approved, 20 of which have been completed/closed to accrual. Results from the first 13 completed TBCRC trials – four in triple negative breast cancer, two in HER2 positive disease, one in endocrine resistant disease, two in hormone receptor negative breast cancer , one in HER2 negative breast cancer, and three non-therapeutic trials– have been presented at national meetings. Five of them have since been published in peer-reviewed journals. Results from another recently completed study in HER2 positive breast cancer was just presented at the American Society of Clinical Oncology (ASCO) 2014 annual meeting. In addition, correlative work from two TBCRC recently completed studies, as well as two “Trial in Progress” presentations were also presented at the ASCO meeting.
The TBCRC network is engaged in other BCRF-funded studies including the Male Breast Cancer International Project (lead investigators, Fatima Cardoso, John Bartlett, Sharon Giordano, John Bartlett and Peggy Porter on behalf of the European Organisation for the Research and Treatment of Cancer (EORTC) and the Evelyn H. Lauder Founder’s Fund (lead investigators, Martin Piccart, Breast International Group, and Nancy Davidson on behalf of North American Breast Cancer Group.)
While male breast cancer is a rare disease accounting for less than 1% of all breast cancers, knowledge about this disease is scarce, and treatment and management is based on female breast cancer. The Male Breast Cancer International Program is a worldwide effort coordinated by the European Organization for the Research and Treatment of Cancer (EORTC) with the help of the TBCRC, and run under the network of the Breast International Group (BIG) and the North American Breast Cancer Groups (NABCG). The objective of the program is to characterize male breast cancer with the goal of developing specific treatments and improving outcomes for men with breast cancer.
The Evelyn H. Lauder Founder’s Fund is an international initiative that was created from the outpouring of contributions to BCRF in honor of Mrs. Lauder, who died in 2011. The objective of the multi-year project is to dissect the molecular underpinning of metastasis. BCRF grantee and member of the Scientific Advisory Board, Dr. Nancy Davidson, leads the US clinical trials group under the administrative oversight of the TBCRC with BCRF grantee Charles Perou overseeing the molecular studies with contributions from Matthew Ellis, Nancy Lin, Andrea Richardson, William F. Symmans and others.
Antonio Wolff received his medical degree from the Universidade Federal do Rio de Janeiro, completed a residency at Mount Sinai (NY) and fellowship at Johns Hopkins. He is a Professor of Oncology at The Johns Hopkins Sidney Kimmel Comprehensive Cancer Center. His research interests include new treatment strategies, the development of prognostic and predictive biomarkers, and survivorship and quality of care. Dr. Wolff was a member of the Breast Cancer Guidelines Committee of the National Comprehensive Cancer Network between 2000 and 2014. He sat on the Clinical Practice Guidelines Committee of the American Society of Clinical Oncology from 2002 to 2008 (Chair, 2006-2007), and was a member of the first ASCO Quality Care Committee. Dr. Wolff is also interested in survivorship, needs assessments, and educational needs of breast cancer patients. At Johns Hopkins, he co-chairs the Cancer Outcomes & Health Services Research Interest Group. He chaired the Cancer Center Clinical Research Scientific Review Committee and was a member of the School of Medicine CME Advisory Board. Since 2006, he has been Executive Officer of the Translational Breast Cancer Research Consortium (www.tbcrc.org), a clinical research consortium that involves all breast cancer SPOREs and major academic breast cancer programs. Dr. Wolff has received research funding from the National Cancer Institute, Avon Foundation, Breast Cancer Research Foundation, and Susan G. Komen Breast Cancer Foundation. In January 2014 he became Co-Chair of the Breast Cancer Committee of ECOG-ACRIN. He is Associate Editor of the Journal of Clinical Oncology.